Elsevier

Modern Pathology

Volume 21, Issue 10, October 2008, Pages 1255-1261
Modern Pathology

Article
Histopathologic variables predict Oncotype DX Recurrence Score

https://doi.org/10.1038/modpathol.2008.54Get rights and content
Under an Elsevier user license
open archive

Abstract

Oncotype DX™ is a commercially available reverse transcriptase-polymerase chain reaction based assay that provides a Recurrence Score (RS) and has been shown to provide prognostic and predictive information in estrogen receptor-positive lymph node-negative breast cancers. Independent studies of its utility in routine practice are lacking. Slides and surgical pathology reports from 42 cases of breast carcinomas evaluated by Oncotype DX™ were retrospectively reviewed to determine patient age, tumor size, histologic grade, estrogen and progesterone receptor (ER and PR) and ERBB2 (HER-2/neu) data, with ER and PR reported as a semi-quantitative score reflecting both intensity of staining and proportion of positive cells. We show here that Recurrence Score is significantly correlated with tubule formation, nuclear grade, mitotic count, ER immunohistochemical score, PR immunohistochemical score, and HER-2/neu status, and that the equation RS=13.424+5.420 (nuclear grade) +5.538 (mitotic count) −0.045 (ER immunohistochemical score) −0.030 (PR immunohistochemical score) +9.486 (HER-2/neu) predicts the Recurrence Score with an R2 of 0.66, indicating that the full model accounts for 66% of the data variability. Although the Oncotype DX™ Recurrence Score holds potential, further validation of its independent value beyond that of histopathologic analysis is necessary before it can be implemented in clinical decision making.

Oncotype Dx™ Recurrence Score
breast cancer

Cited by (0)

Disclosure/conflict of interest

None of the authors have any conflict of interest with the materials presented in this paper.

Presented in part at the International Academy of Pathology meeting in Montreal, QC, Canada; September 16–21, 2006.